Select Your Region
Global
A clinical trial to understand how genetic testing can help doctors to decide which treatment is best for patients with solid tumours (TAPISTRY)
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- Cancer
- Solid Tumors
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:
Active, not recruiting
This trial runs in
Cities
- Aarhus
- Albuquerque
- Ann Arbor
- Athens
- Auckland
- Aurora
- Austin
- Basel
- bei-jing-shi
- Beijing
- Bern
- Billings
- Boise
- Bordeaux
- Brescia
- broomall
- Bruxelles
- chang-chun-shi
- Charleroi
- cheng-du-shi
- Chuo City
- Cincinnati
- Dallas
- Darlinghurst
- Detroit
- Duarte
- Edegem
- Esplugues de Llobregat
- Essen
- Firenze
- Fort Worth
- Gdańsk
- Gent
- Germantown
- Glasgow
- Goodyear
- Göttingen
- Haifa
- Hamburg
- Hannover
- Heilbronn
- horsham
- Houston
- Jerusalem
- Johannesburg
- Kashiwa
- København
- Lebanon
- Leesburg
- Leuven
- Lille
- Lombardy
- London
- Los Angeles
- Lyon
- Madrid
- Manchester
- Marseille
- Melbourne
- Memphis
- Miami
- Milano
- Milwaukee
- Minneapolis
- Montréal
- Mönchengladbach
- München
- Napoli
- New Brunswick
- New Territories
- New York
- Ocala
- Omaha
- Osakasayama
- Ottawa
- Parkville
- Petah Tikva
- Philadelphia
- Porto
- Ramat Gan
- Randwick
- Roma
- Rome
- San Juan
- sant-andreu-de-la-barca
- Santa Monica
- Seongnam-si
- Seoul
- shang-hai-shi
- Siena
- Silver Spring
- Singapore
- São Paulo
- Tacoma
- Taichung City
- Tainan City
- Taipei City
- Taoyuan City
- Tel Aviv-Yafo
- tian-jin-shi
- tiwi
- Torino
- Toronto
- Toulouse
- Tyler
- Ulm
- València
- Vancouver
- Villejuif
- Warszawa
- Woolloongabba
- Würzburg
- xi-an-shi
- Zion
- Zürich
Trial Identifier:
NCT04589845 2020-001847-16 BO41932
Trial Summary
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors will be treated with a drug or drug regimen tailored to their NGS assay results at screening. Participants will be assigned to the appropriate cohort based on their genetic alteration(s). Treatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.
Hoffmann-La Roche
Sponsor
Phase 2
Phase
NCT04589845,BO41932,2020-001847-16
Trial Identifier
Entrectinib, Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine, Idasanutlin, Inavolisib, Belvarafenib, Pralsetinib, GDC-6036, Camonsertib
Treatments
Solid Tumors
Condition
Official Title
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
Eligibility Criteria
All
Gender
No
Healthy Volunteers
Inclusion Criteria
- Histologically or cytologically confirmed diagnosis of advanced and unresectable or metastatic solid malignancy
- Measurable disease as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), Response Assessment in Neuro-Oncology (RANO) criteria, or International Neuroblastoma Response Criteria (INRC)
- Performance status as follows: Participantss aged >= 18 years: Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2; Participantss aged 16 to < 18 years: Karnofsky score >= 50%; Participants aged < 16 years: Lansky score >= 50%
- For participants aged >= 18 and <18 years: adequate hematologic and end-organ function
- Disease progression on prior treatment, or previously untreated disease with no available acceptable treatment
- Adequate recovery from most recent systemic or local treatment for cancer
- Life expectancy >= 8 weeks
- Ability to comply with the study protocol, in the investigator's judgment
- For female participants of childbearing potential: Negative serum pregnancy test <= 14 days prior to initiating study treatment; agreement to remain abstinent or use single or combined contraception methods that result in a failure rate of < 1% per year for the period defined in the cohort-specific inclusion criteria; and agreement to refrain from donating eggs during the same period
- For male participants: Willingness to remain abstinent or use acceptable methods of contraception as defined in the cohort-specific inclusion criteria
- In addition to the general inclusion criteria above, participants must meet all of the cohort-specific inclusion criteria for the respective cohort
Exclusion Criteria
- Current participation or enrollment in another therapeutic clinical trial
- Any anticancer treatment within 2 weeks or 5 half-lives prior to start of study treatment
- Whole brain radiotherapy within 14 days prior to start of study treatment
- Stereotactic radiosurgery within 7 days prior to start of study treatment
- Pregnant or breastfeeding, or intending to become pregnant during the study
- History of or concurrent serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study or confounds the ability to interpret data from the study
- Incomplete recovery from any surgery prior to the start of study treatment that would interfere with the determination of safety or efficacy of study treatment
- Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or higher), myocardial infarction, or cerebrovascular accident within 3 months prior to enrollment, unstable arrhythmias, or unstable angina
- History of another active cancer within 5 years prior to screening that may interfere with the determination of safety or efficacy of study treatment with respect to the qualifying solid tumor malignancy
- In addition to the general exclusion criteria above, in order to be enrolled in a treatment cohort of the study, participants must not meet any of the cohort-specific exclusion criteria
For the latest version of this information please go to www.forpatients.roche.com